Genmab — Maj 2020

[Sukkeralf]

if it is

[StockBull]

ser ikke nogen prop i 1979 nu ca. 400 aktier til salg op til 1981

[StockBull]

356 nu

[StockBull]

så rykkede vi over 1980

[StockBull]

vi skal over 2100 i ugens løb hvis markedet er positivt kommende 3 dage

[StockBull]

partnerdealen rykker os over 2300 inden ASCO

[StockBull]

så blev den sku banket ned igen til 1976. Tror det er en fælde for at fravriste nervøse genmab fold deres billige aktier

[E_L]

@14:24 also heard have already 5 in the clinic, but i think he was pointing at CD3 redirectors (i believe we 6 duobodies?) and 2 more by the end of the year, but he did not say if these are DuoBody

[E_L]

teclistamab ; mentioned tox profile very favourable (no grade 3 or 4) - response rate at least 69% -and importantly,
improving over time

[E_L]

Dara -more at EHA/ASH -SC critically important -next generation combinations, incl comb with CD3 redirectors -we will be building on Darzalex with new regimens with more therapeutics coming

[E_L]

Solids: Amivantamab -really excited about mechanism -many bispecifics have not been successful; this one clearly very active -degrades egfr receptor so that it can't act -also degrades cmet receptor which is often activated and amplified in NSCLC -enahced ADCC so it brings an immune killing component -so mulitple ways in going after the tumor

[E_L]

-we believe there are other areas where this AB can work beyond exon-20

[E_L]

-patients post platinum chemo, so already had most active regiment the can get

[E_L]

ORR 41% with 10month median duration , so this is really strong data

[E_L]

other important point; combo with own egfr small molecule inhibitor, combos probably have a better response and more durable; need to start doing those studies and move them along

[StockBull]

Pensionist. Ja kursen bliver holdt mellem 1970 og 1980. Det kan være en der tager profit, en shorter eller lige mange som vil ind /ud på niveauet. Mon ikke bare aktien tager en puster og fortsætter med de 3000 når der er taget profit. Jeg ville ikke shorte lige inden asco og en evt. partnerdeal men muligvis efter

[Helge_LarsenPI-redaktør]

For mig ligner det en algo som styrer et tradinginterval med henblik på akkumulering.

[Helge_LarsenPI-redaktør]

Dagsgrafen viser det tydeligt. Ligner klingen på en fukssvans.

[Solsen]

Evt shortere saves midt over

[E_L]

Genmab Success in the Netherlands is Powered by Innovative Life Sciences Ecosystem https://investinholland.com/success-stories/genmab/